Revance company information, Employees & Contact Information

Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation PR Newswire

Revance Celebrates Distribution of One Million Vials of DAXXIFY® in the U.S. Yahoo Finance

Survey reveals few can name ingredients in injectable beauty treatments Talker Research

Crown Laboratories Completes Acquisition of Revance Therapeutics Business Wire

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer Yahoo Finance

Revance Therapeutics, Inc. SEC 10-Q Report TradingView

Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville TN.gov

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) Yahoo Finance

Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer PR Newswire

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement PR Newswire

Crown Laboratories and Revance Announce Entry Into Merger Agreement PR Newswire

Revance Expands Leadership Team with Key Executive Appointments PR Newswire

Revance Launches the Teoxane RHA® Collection with Mepivacaine PR Newswire

Revance Announces Launch of New PanOxyl® Acne Gel Wash and Daytime Invisible Patches PR Newswire

An Exciting New Face for StriVectin®: A Modern Website for a Science-Based Skincare Brand PR Newswire

Crown Laboratories Now Operates Under the Name Revance PR Newswire

Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day PR Newswire

Revance Announces Blue Lizard® Australian Sunscreen Named the #1 Selling Mineral Sunscreen Brand PR Newswire

New Survey Reveals Consumer Blind Spot: Ingredient Awareness Is Booming Across Beauty & Wellness -- But Consumers Overlook What's in Their Aesthetic Treatments PR Newswire

Full article: A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product Taylor & Francis Online

FDA Accepts sBLA for Revance’s Cervical Dystonia Treatment DaxibotulinumtoxinA NeurologyLive

Major Biotech Deal: Revance Shareholders Back Crown Labs Takeover with Massive 82% Support Rate Stock Titan

Revance Announces FDA Approval of DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results Business Wire

Crown Laboratories Announces Appointment of Adelle Walker as Chief Marketing Officer, Aesthetics PR Newswire

PanOxyl® BPO Acne Treatment Bar Wins Coveted Allure Best of Beauty Award PR Newswire

Revance Announces the Launch of OPUL , the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices Business Wire

Introducing DaxibotulinumtoxinA-Ianm as a Treatment Option for Cervical Dystonia: Peter J. McAllister, MD, FAAN NeurologyLive

BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco PR Newswire

FDA-Approved Injection DaxibotulinumtoxinA Shows Efficacy for Cervical Dystonia Treatment in Phase 3 ASPEN-1 Trial NeurologyLive

FDA Accepts BLA Resubmission for DAXI Injections Dermatology Times

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Nasdaq

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FinancialContent

Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices Business Wire

Crown Laboratories, Inc. Announces PanOxyl® Acne Wash Has Been Certified as the #1 Selling Acne Wash in Canada PR Newswire Canada

Revance Announces Blue Lizard Australian Sunscreen® Partnership with The Bentway for Their Summer 2025 Sun/Shade Program PR Newswire Canada

Revance Announces China Market License Agreement with Fosun Pharma for RT002 NAI500

Cervical Dystonia Drug Candidate Gets Orphan Drug Designation Medical Professionals Reference